GGrantIndex
← Leaderboards

Timothy R Zacharewski

Michigan State University

Google Scholar ↗PubMed ↗ORCID ↗
$14,815,146
Attributed
$14,815,146
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $3M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,999,360 · 13

By mechanism

R01$8,892,221 · 5
P42$7,871,260 · 5
R21$2,235,879 · 3

Top collaborators

No co-investigators on record.

Most similar at Michigan State University

Same institution · by research overlap

Others in their field

Top investigators on “Dose”

Research focus

DoseGene ExpressionDioxinsResponsePathway InteractionsMediatingToxic EffectLiverTetrachlorodibenzodioxinFatty LiverLinkHepatocyteAryl Hydrocarbon ReceptorHepaticHepatotoxicityAryl Hydrocarbon Receptor LigandPlayPrimary Carcinoma Of The Liver CellsCellsReceptor ActivationLipidsMetabolismExposure ToLigands

Grant awards (47)

Environmental, Microbial and Mammalian Biomolecular Responses to AhR Ligands$2,120,146
P42 · FY2025 · ES · contact PI
Toxic lipid intermediate accumulation and cobalamin depletion promote AHR-mediated hepatotoxicity and the progression of non-alcoholic fatty liver disease (NAFLD)-like pathologies$551,938
R01 · FY2025 · ES · contact PI
Project 3 - The role of HMGCR in Modulating TCDD-induced, AHR-mediated NAFLD$308,935
P42 · FY2025 · ES · contact PI
Environmental, Microbial and Mammalian Biomolecular Responses to AhR Ligands$2,064,068
P42 · FY2024 · ES · contact PI
Project 3 - The role of HMGCR in Modulating TCDD-induced, AHR-mediated NAFLD$302,577
P42 · FY2024 · ES · contact PI
AhR-dependent Pkm2 regulation in NAFLD progression$341,376
R01 · FY2023 · ES · contact PI
Project 3 - The role of HMGCR in Modulating TCDD-induced, AHR-mediated NAFLD$307,315
P42 · FY2023 · ES · contact PI
Toxic lipid intermediate accumulation and cobalamin depletion promote AHR-mediated hepatotoxicity and the progression of non-alcoholic fatty liver disease (NAFLD)-like pathologies$1,565,100
R01 · FY2022 · ES · contact PI
AhR-dependent Pkm2 regulation in NAFLD progression$341,659
R01 · FY2022 · ES · contact PI
Project 3 - The role of HMGCR in Modulating TCDD-induced, AHR-mediated NAFLD$307,753
P42 · FY2022 · ES · contact PI
AhR-dependent Pkm2 regulation in NAFLD progression$40,318
R01 · FY2022 · ES · contact PI
AhR-dependent Pkm2 regulation in NAFLD progression$448,088
R01 · FY2021 · ES · contact PI
AhR-dependent Pkm2 regulation in NAFLD progression$342,194
R01 · FY2020 · ES · contact PI
Advancing chemical and drug safety testing using single-cell RNA-sequencing$195,625
R21 · FY2020 · HG · contact PI
Advancing chemical and drug safety testing using single-cell RNA-sequencing$71,866
R21 · FY2020 · HG · contact PI
AhR-dependent Pkm2 regulation in NAFLD progression$65,838
R01 · FY2020 · ES · contact PI
AhR-dependent Pkm2 regulation in NAFLD progression$342,446
R01 · FY2019 · ES · contact PI
Advancing chemical and drug safety testing using single-cell RNA-sequencing$234,750
R21 · FY2019 · HG · contact PI
Project 3: TCDD-Elicited Steatosis: The Role of Aryl Hydrocarbon Receptor$280,539
P42 · FY2017 · ES · contact PI
Project 3: TCDD-Elicited Steatosis: The Role of Aryl Hydrocarbon Receptor$240,218
P42 · FY2016 · ES · contact PI
Project 3: TCDD-Elicited Steatosis: The Role of Aryl Hydrocarbon Receptor$255,801
P42 · FY2015 · ES · contact PI
Project 3: TCDD-Elicited Steatosis: The Role of Aryl Hydrocarbon Receptor$258,151
P42 · FY2014 · ES · contact PI
Project 3: TCDD-Elicited Steatosis: The Role of Aryl Hydrocarbon Receptor$4,162
P42 · FY2014 · ES · contact PI
Project 3: TCDD-Elicited Steatosis: The Role of Aryl Hydrocarbon Receptor$246,664
P42 · FY2013 · ES · contact PI
Non-Additive Ah Receptor Ligand Interactions$241,759
P42 · FY2010 · ES · contact PI
Metabolomic Assessment of Estrogenic Endocrine Disruptor$536,571
R01 · FY2009 · ES · contact PI
Non-Additive Ah Receptor Ligand Interactions$237,348
P42 · FY2009 · ES · contact PI
Metabolomic Assessment of Estrogenic Endocrine Disruptor$535,031
R01 · FY2008 · ES · contact PI
Human Stem Cells for Toxicity Screening(RMI)$351,137
R21 · FY2008 · GM · contact PI
Non-Additive Ah Receptor Ligand Interactions$233,051
P42 · FY2008 · ES · contact PI
Metabolomic Assessment of Estrogenic Endocrine Disruptor$543,226
R01 · FY2007 · ES · contact PI
Human Stem Cells for Toxicity Screening(RMI)$357,938
R21 · FY2007 · GM · contact PI
Non-Additive Ah Receptor Ligand Interactions$241,514
P42 · FY2007 · ES · contact PI
Metabolomic Assessment of Estrogenic Endocrine Disruptor$565,784
R01 · FY2006 · ES · contact PI
Human Stem Cells for Toxicity Screening$368,629
R21 · FY2006 · GM · contact PI
Non-Additive Ah Receptor Ligand Interactions$221,259
P42 · FY2006 · ES · contact PI
Metabolomic Assessment of Estrogenic Endocrine Disruptor$617,117
R01 · FY2005 · ES
Human Stem Cells for Toxicity Screening(RMI)$377,500
R21 · FY2005 · GM
Ah Receptor-Mediated Ligand Toxicity$355,063
R01 · FY2005 · ES
Ah Receptor-Mediated Ligand Toxicity$355,063
R01 · FY2004 · ES
Ah Receptor-Mediated Ligand Toxicity$354,963
R01 · FY2003 · ES
Comprehensive Assessment of Endocrine Active Mixtures$349,945
R01 · FY2003 · ES
Neurotoxicant Disruption of Astroglial Differentiation$132,917
R21 · FY2003 · ES
Comprehensive Assessment of Endocrine Active Mixtures$280,270
R01 · FY2002 · ES
Neurotoxicant Disruption of Astroglial Differentiation$145,517
R21 · FY2002 · ES
Comprehensive Assessment of Endocrine Active Mixtures$68,013
R01 · FY2002 · ES
Comprehensive Assessment of Endocrine Active Mixtures$292,218
R01 · FY2001 · ES